FTC Nominee Khan Is Likely To Face Close Senate Vote; Biden Still Has One More Seat To Fill
Executive Summary
Columbia’s Khan is known for her critical views of tech industry, which observers expect will transfer to pharma; another possible nominee for the other remaining spot, DC attorney general Karl Racine, is also focused on the tech space. Acting Chair Rebecca Kelly Slaughter’s pharma interest likely means the issue won’t recede from the FTC’s agenda.
You may also be interested in...
Pharma Mergers May Have Tougher Time Clearing FTC Under New Review Scheme
FTC is working with Canadian and European enforcement agencies to come up with new approach to merger reviews that could look at effects on innovation and companies' past conduct. FTC to review closed mergers to see if corrective action is necessary, FTC acting chair says.
FTC Shift Under Biden Administration Begins With Chairman Simons, Senior Staff Resigning
While expected following start of Biden administration, Simon’s resignation is “somewhat of a surprise” considering it will change the balance of power to the Democrats ahead of when his term would have been ended, says advertising law attorney Ivan Wasserman.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.